Dynamic Technology Lab Private Ltd Purchases New Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Dynamic Technology Lab Private Ltd bought a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,894 shares of the company's stock, valued at approximately $1,252,000. Dynamic Technology Lab Private Ltd owned about 0.16% of Castle Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC boosted its position in shares of Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company's stock valued at $123,000 after buying an additional 1,522 shares during the last quarter. US Bancorp DE raised its position in Castle Biosciences by 1,889.2% in the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company's stock worth $132,000 after buying an additional 4,383 shares during the last quarter. Assetmark Inc. raised its position in Castle Biosciences by 16.8% in the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company's stock worth $149,000 after buying an additional 748 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company's stock worth $152,000 after buying an additional 2,093 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Castle Biosciences in the 3rd quarter worth about $236,000. Institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Castle Biosciences

In related news, insider Tobin W. Juvenal sold 3,507 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now owns 54,178 shares in the company, valued at approximately $1,926,569.68. This trade represents a 6.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 1,972 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $34.15, for a total value of $67,343.80. Following the sale, the insider now owns 87,720 shares of the company's stock, valued at $2,995,638. This represents a 2.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,213 shares of company stock valued at $752,673 over the last ninety days. 7.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CSTL shares. Canaccord Genuity Group boosted their target price on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, October 29th. Scotiabank boosted their target price on Castle Biosciences from $37.00 to $44.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, November 6th. KeyCorp boosted their target price on Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. BTIG Research boosted their target price on Castle Biosciences from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Finally, Stephens reaffirmed an "overweight" rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $37.88.

Castle Biosciences Trading Up 3.6 %

Castle Biosciences stock opened at $30.57 on Wednesday. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm has a market capitalization of $856.27 million, a price-to-earnings ratio of 152.86 and a beta of 0.99. The firm has a 50 day moving average of $30.94 and a 200 day moving average of $26.58. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The firm had revenue of $85.78 million during the quarter, compared to analysts' expectations of $78.55 million. During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, research analysts predict that Castle Biosciences, Inc. will post -0.08 earnings per share for the current year.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.